Ependymoma: Symptoms, Molecular Classification, Treatment, and Prognosis
Ependymomas are glial tumors arising from ependymal cells lining the cerebral ventricles and spinal cord central canal. They occur across the lifespan with bimodal peaks: young children (<5 years, posterior fossa) and adults 30-40 years (spinal > supratentorial). Molecular subgroups now define prognosis and therapy more than histology alone.
Molecular Classification (WHO CNS5)
| Location | Molecular Group | Key Features |
| Posterior Fossa (PF) | PF-EPN-A (H3K27me3 loss / EZHIP overexpression) | Infants/young children, balanced genome, poor prognosis |
| Posterior Fossa | PF-EPN-B (intact H3K27me3) | Older children/adults, 1q gain common, better prognosis |
| Supratentorial (ST) | ST-EPN-RELA (C11orf95-RELA fusion) | Children/young adults, ~70% ST, aggressive |
| Supratentorial | ST-EPN-YAP1 (YAP1 fusions) | Infants, better prognosis |
| Spinal | SP-EPN (MYCN amplification in subset) | Adults, MYCN-amp = worse; otherwise excellent prognosis |
Clinical Presentation
- Intracranial (PF/ST): Headache (morning, positional), nausea/vomiting (raised ICP), ataxia, cranial nerve palsies (VI, VII), seizures (ST), cognitive/personality changes.
- Spinal: Back pain (nocturnal, radicular), sensory loss, weakness, bowel/bladder dysfunction, Lhermitte's sign.
Risk Factors
- Age (bimodal), slight male predominance.
- Prior cranial/spinal radiation (therapy-related, latency 10-20 yrs).
- Genetic syndromes: NF2 (spinal), Turcot (APC/MUTYH).
Treatment Paradigm
1. Maximal Safe Resection — The Strongest Prognostic Factor
- Gross Total Resection (GTR): 5-yr PFS 70-80% (PF), >90% (spinal).
- Subtotal/biopsy only: Significantly worse.
- Neuromonitoring (MEPs, SSEPs, cranial nerve EMG) essential.
2. Radiotherapy
- PF-EPN-A / ST-EPN-RELA / Grade 3: Post-op focal RT 54-59.4 Gy standard.
- PF-EPN-B / Grade 2 GTR: Observation vs. RT debated; many defer.
- Spinal: RT for residual/recurrent, Grade 3, or MYCN-amp.
- Proton therapy: Reduces dose to cochlea (hearing), hypothalamus/pituitary (endocrine), temporal lobes (neurocognition), heart/lungs (spinal). Preferred for children.
3. Chemotherapy
- Role less defined than medulloblastoma.
- Used for: Very young children (<3-4 yr) to defer RT; recurrent/progressive disease; metastatic.
- Regimens: Platinum-based (cisplatin/etoposide/cyclophosphamide), temozolomide, high-dose chemo + autologous stem cell rescue (experimental).
Prognosis & Surveillance
- 5-yr OS: ~65-85% overall (varies by location, grade, molecular group, resection extent).
- Spinal > Supratentorial > Posterior Fossa (PF-EPN-A worst).
- Late recurrence possible (>10 yrs) — lifelong surveillance.
- Late effects: Neurocognitive (RT), endocrine (hypothalamic-pituitary), hearing (cisplatin/RT), secondary malignancies.
Ependymoma management hinges on maximal safe surgery, molecularly-informed radiation decisions, and lifelong multidisciplinary follow-up for cure and quality of survival.
Lymphoma - Related Articles